NVO
Novo Nordisk ADR
$50.43+3.40%
Setup
Watch
Buy Zone
$51.46-$54.03
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
68
Recommendation
Extended
Watch
Setup may be valid but price is no longer in a clean buy zone.
NVO chart
Loading chart…
Overall Quality68
RS Rating
11
relative strength
Fundamentals
89
Strong fund-Q
Volume Demand
82
-19% vs avg
Technical Setup
63
5/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Extended
Entry
$51.46
Entry Zone
$51.46-$54.03
Stop / Risk
$47.34
RS Rating
11
Volume confirmed
Yes
Targets
$61.75 / $64.33
Breakout · IBD Setup
3 ✓ 5 ✗
Entry $51.46–$54.03Stop $47.34Target $61.75 / $64.33
Market regimeRange
Quality68
RS Rating11
Above 50-MA+13.38%
Above 200-MA+5.43%
VolumeConfirmed
In Buy ZoneNo
Not extendedExtended
Invalidation · Close below stop
How this came together
68
MarketRange
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q89 · Strong
StatusWatch
Stock Data
52-Week Range35 – 72
Price % Chg YTD-0.88%
Price % Chg 4wk17.5%
50-Day Avg Vol14.9 Mil
P/E Ratio11.3
Market Cap$161B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)86.54%
Sales % Chg (Qtr)37.63%
EPS Growth 5y20.36%
Sales Growth 5y19.21%
Annual ROE73.79%
Gross Margin81.84%
Operating Margin45.45%
Net Margin37.23%
Debt / Equity0.72
Setup levels
Current price
$50.43
Pivot
$51.46
Distance to buy
-29.8%
52-week range
35.12-71.8
Trigger evidence
No active trigger evidence available.
Pattern levels: near highs
Financial health checks
5/5
Return on equity above 15%
ROE 73.79%
Net margin above 10%
Net margin 37.23%
EPS growing quarter on quarter
EPS q/q 86.54%
Sales growing quarter on quarter
Sales q/q 37.63%
Debt to equity below 1.0
D/E 0.72
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE73.79%
vs sector +50.8%
Net margin37.23%
vs sector +17.9%
Gross margin81.84%
vs sector +10.2%
EPS growth q/q86.54%
vs sector +67.3%
Sales growth q/q37.63%
vs sector +16.5%
Debt / equity0.72
vs sector +0.00
Business quality
89
GradeStrong
EPS rating79
P/E11.3
Market cap$161B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Fail
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-06-29
Trigger date
—
Days on list
5
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.